What are the recommended starting doses and titration guidelines for amino acid administration in adults, including adjustments for critical illness, renal disease, and hepatic insufficiency?

Amino Acid Administration in Adults: Dosing and Titration Guidelines

For critically ill adults, start with 1.2-1.5 g/kg/day of protein/amino acids, titrating up to 1.5-1.7 g/kg/day for those on continuous renal replacement therapy (CRRT), while patients with chronic kidney disease not on dialysis should receive 0.6-0.8 g/kg/day, and those with hepatic insufficiency should receive 1.2-1.5 g/kg/day using standard formulas rather than disease-specific preparations. 1

Critical Illness Without Organ Failure

For critically ill patients without acute kidney injury (AKI) or chronic kidney disease (CKD):

• Starting dose: 1.0 g/kg/day
• Titration: Gradually increase to 1.3 g/kg/day if tolerated 1
• Evidence supports that 2.0-2.5 g/kg/day may be safe and optimal for the most critically ill adults to decrease morbidity and mortality 2

The 2024 PROTECTION trial demonstrated that intravenous amino acids at 2 g/kg ideal body weight/day reduced acute kidney injury occurrence (26.9% vs 31.7%, RR 0.85) in cardiac surgery patients, suggesting higher doses may provide organ protection 3. However, this was a specific surgical population, so extrapolation requires caution.

Renal Disease Adjustments

Chronic Kidney Disease (Not on Dialysis, No Critical Illness)

• Dose: 0.6-0.8 g/kg/day 1
• This lower intake prevents uremic toxin accumulation while preserving nitrogen balance

AKI Without Dialysis (Critical Illness)

• Starting dose: 1.0 g/kg/day
• Target: Up to 1.3 g/kg/day if tolerated 1

AKI or CKD on Intermittent Hemodialysis (Critical Illness)

• Dose: 1.3-1.5 g/kg/day 1
• Dialysis removes amino acids, necessitating higher replacement

AKI or CKD on CRRT or Prolonged Intermittent KRT (Critical Illness)

• Dose: 1.5-1.7 g/kg/day 1
• Rationale: Continuous therapies cause substantial amino acid losses
• Studies show that 2.0-2.5 g/kg/day can achieve near-positive nitrogen balance in CRRT patients, though this may increase blood urea nitrogen and CRRT requirements 1

Critical caveat: Do NOT reduce protein intake to avoid or delay dialysis initiation—protein catabolism in AKI is minimally influenced by intake, and restriction worsens muscle wasting without preventing dialysis 1. A 2015 trial showed amino acid supplementation improved estimated GFR and urine output in critically ill patients, though it did not reduce duration of renal dysfunction 4.

Body Weight Considerations for Dosing

• Preferred: Pre-hospitalization or usual body weight 1
• Avoid: Actual body weight in fluid-overloaded patients (overestimates needs in those on dialysis, underestimates in those not on dialysis) 1
• Calculate: Protein catabolic rate when possible to guide individualized dosing 1

Hepatic Insufficiency Adjustments

Acute Liver Failure (ALF)

• Energy: 30-35 kcal/kg/day
• Protein: 1.2-1.5 g/kg/day 5
• Formula type: Standard enteral formulas—no evidence supports disease-specific formulas 5
• Route: Enteral nutrition preferred; start with low doses regardless of hepatic encephalopathy grade 5
• Parenteral nutrition: Second-line when enteral feeding inadequate 5

The evidence does NOT support routine use of branched-chain amino acid (BCAA) formulas in critically ill liver patients. While BCAAs may reduce hepatic encephalopathy manifestations (RR 0.79), the evidence is low certainty and shows no mortality benefit 6. Standard whole-protein formulations are appropriate 5.

Decompensated Cirrhosis with Hepatic Encephalopathy

• Protein: 1.2-1.5 g/kg/day 5
• Do NOT restrict protein—this worsens malnutrition without improving encephalopathy
• Standard formulas are adequate; BCAA-enriched formulas show uncertain benefit 5, 6

Cirrhosis with End-Stage Kidney Disease

• Special consideration: BCAA infusion may reduce mortality in this dual-organ failure population, particularly Child-Pugh class C patients (mortality 16.2% vs 39.0% without BCAAs) 7
• This represents a specific exception where BCAAs may be beneficial

Practical Implementation Algorithm

1. Determine baseline status:

   • Kidney function (CKD stage, dialysis type if applicable)
   • Liver function (cirrhosis, acute failure, encephalopathy grade)
   • Critical illness severity

2. Select starting dose based on above categories

3. Monitor for tolerance:

   • Blood urea nitrogen (expect increases with higher protein loads)
   • Nitrogen balance if feasible
   • Fluid balance
   • Ammonia levels in liver disease

4. Titrate upward if:

   • Negative nitrogen balance persists
   • No uremic complications
   • Adequate dialysis clearance available

5. Avoid overfeeding: Calories >40-60 kcal/kg worsen protein catabolism and nitrogen balance 1

Common Pitfalls

• Restricting protein to delay dialysis: This is harmful and ineffective 1
• Using actual body weight in edematous patients: Leads to inappropriate dosing 1
• Assuming BCAA formulas are superior: Standard formulas work equally well in most situations 5
• Inadequate protein in dialysis patients: Dialysis losses are substantial and require compensation 1